Novo Nordisk's ziltivekimab failed to reduce major adverse cardiovascular events despite demonstrating target engagement and IL-6 pathway inhibition.
FirstSquawk07/31, 06:23 PM
Related assets
Coming up for NOVO
Explore next
Latest NOVO news
Finnhub08/19, 05:10 PM
FirstSquawk08/04, 11:41 PM
FirstSquawk08/04, 11:41 PM